---
title: "Inogen Maintains Buy Rating as Analyst Reaffirms $12 Price Target on Solid Q1 and Growth Catalysts"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285707117.md"
description: "Michael Matson from Needham has maintained a Buy rating on Inogen with a price target of $12.00, citing strong Q1 2026 revenue and EBITDA performance. He noted that international sales exceeded expectations, while U.S. sales met forecasts, and margins improved year over year. Matson anticipates that upcoming product launches will drive further growth, despite a slight slowdown in constant-currency growth. He believes Inogen's diversification strategy will enhance long-term growth and profitability, justifying his price target and rating."
datetime: "2026-05-08T10:01:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285707117.md)
  - [en](https://longbridge.com/en/news/285707117.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285707117.md)
---

# Inogen Maintains Buy Rating as Analyst Reaffirms $12 Price Target on Solid Q1 and Growth Catalysts

In a report released today, Michael Matson from Needham maintained a Buy rating on Inogen, with a price target of $12.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Michael Matson has given his Buy rating due to a combination of factors, including Inogen’s better‑than‑expected first‑quarter 2026 revenue and adjusted EBITDA performance, as well as stable full‑year guidance. He also notes that international sales outpaced expectations, U.S. sales were in line, and margin expansion continued, with both gross and EBITDA margins improving year over year.

Matson highlights that Inogen has returned to mid‑single‑digit revenue growth and views upcoming product launches, such as the Voxi 5 stationary concentrator and Aurora CPAP mask, as potential catalysts for stronger growth in 2026. Despite a modest slowdown in constant‑currency growth in the quarter, he believes the company’s ongoing diversification strategy positions it for better long‑term growth and profitability, supporting his unchanged $12 price target and Buy rating.

### Related Stocks

- [INGN.US](https://longbridge.com/en/quote/INGN.US.md)

## Related News & Research

- [Inogen: Aurora CPAP Launch and Expanding Respiratory Portfolio Underpin Buy Rating](https://longbridge.com/en/news/271815865.md)
- [Top Matson Executives Quietly Unload Shares in Back-to-Back Insider Moves](https://longbridge.com/en/news/286630055.md)
- [What is next for Energy Transfer after its 2026 guidance hike?](https://longbridge.com/en/news/287100206.md)
- [This relentless bull market is about to face its biggest test yet](https://longbridge.com/en/news/287052391.md)
- [America’s consumer divide is growing](https://longbridge.com/en/news/287105871.md)